Responses
Scientific Abstracts
Late Breaking Abstracts
Late Breaking Abstract Session
LB0001 Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study (rapid-PSA)
Compose a Response to This Article
Other responses
No responses have been published for this article.